ANIX Stock Overview
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases.
Anixa Biosciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.37|
|52 Week High||US$5.87|
|52 Week Low||US$2.30|
|1 Month Change||28.63%|
|3 Month Change||11.96%|
|1 Year Change||-9.41%|
|3 Year Change||-21.08%|
|5 Year Change||237.00%|
|Change since IPO||-96.04%|
Recent News & Updates
Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably. Trial enrollment for the vaccine trial was fast, and the company seems optimistic about the near-term future of the company. The market is huge, and if the trial is successful, chances are we are seeing the beginning of a huge spike in share price. 2022 will, in any case, be the year for Anixa, with other programs ongoing as well.
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|ANIX||US Biotechs||US Market|
Return vs Industry: ANIX exceeded the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: ANIX matched the US Market which returned -10.4% over the past year.
|ANIX Average Weekly Movement||11.0%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ANIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ANIX's weekly volatility (11%) has been stable over the past year.
About the Company
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer.
Anixa Biosciences Fundamentals Summary
|ANIX fundamental statistics|
Is ANIX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANIX income statement (TTM)|
|Cost of Revenue||US$2.00|
Last Reported Earnings
Jan 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.48|
|Net Profit Margin||2,915,080.00%|
How did ANIX perform over the long term?See historical performance and comparison
Is Anixa Biosciences undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ANIX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ANIX's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: ANIX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ANIX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANIX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ANIX is overvalued based on its PB Ratio (3x) compared to the US Biotechs industry average (1.4x).
How is Anixa Biosciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANIX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ANIX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ANIX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ANIX is forecast to have no revenue next year.
High Growth Revenue: ANIX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ANIX's Return on Equity is forecast to be high in 3 years time
How has Anixa Biosciences performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANIX is currently unprofitable.
Growing Profit Margin: ANIX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ANIX is unprofitable, and losses have increased over the past 5 years at a rate of 10% per year.
Accelerating Growth: Unable to compare ANIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: ANIX has a negative Return on Equity (-44.45%), as it is currently unprofitable.
How is Anixa Biosciences's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ANIX's short term assets ($35.0M) exceed its short term liabilities ($1.8M).
Long Term Liabilities: ANIX's short term assets ($35.0M) exceed its long term liabilities ($209.0K).
Debt to Equity History and Analysis
Debt Level: ANIX is debt free.
Reducing Debt: ANIX currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANIX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ANIX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 8.4% each year
What is Anixa Biosciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ANIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ANIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ANIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ANIX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ANIX has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Amit Kumar (57 yo)
Dr. Amit Kumar, Ph.D. is a Director at Ascent Solar Technologies, Inc. since June 2007 and has been its Independent Chairman of the Board since January 2011. Dr. Kumar is the Chief Executive Officer at Ani...
CEO Compensation Analysis
Compensation vs Market: Amit's total compensation ($USD10.96M) is above average for companies of similar size in the US market ($USD770.21K).
Compensation vs Earnings: Amit's compensation has increased whilst the company is unprofitable.
Experienced Management: ANIX's management team is considered experienced (4.8 years average tenure).
Experienced Board: ANIX's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ANIX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Anixa Biosciences, Inc.'s employee growth, exchange listings and data sources
- Name: Anixa Biosciences, Inc.
- Ticker: ANIX
- Exchange: NasdaqCM
- Founded: 1982
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$101.613m
- Shares outstanding: 30.15m
- Website: https://www.anixa.com
Number of Employees
- Anixa Biosciences, Inc.
- 3150 Almaden Expressway
- Suite 250
- San Jose
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.